(Q83367463)
Statements
Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia (English)
Guillermo Garcia-Manero
Hagop M Kantarjian
Moshe Talpaz
Susan O'Brien
Daniel Jones
Francis Giles
Stefan Faderl
Farhad Ravandi
Mary Beth Rios
Jianqin Shan